Molecular classification and adjuvant treatment in endometrioid endometrial cancer with microcystic elongated and fragmented (MELF) invasion pattern

Table 3 Characteristics of patients with recurrence

Case NO.	Age	BMI (kg/m2)	stage	Molecular Subtype	FIGO Grade	Tumor Size (cm)	ESMO-Risk	MI	CSI	LVSI	LN	IHC						Adjuvant Therapy	Relapse	DFS (m)
Case NO.	Age	BMI (kg/m2)	stage	Molecular Subtype	FIGO Grade	Tumor Size (cm)	ESMO-Risk	MI	CSI	LVSI	LN	MMR	ER	PR	PTEN	Ki67 (%)	P53	Adjuvant Therapy	Relapse	DFS (m)
1	68	27.27	IA	dMMR	2	3.5	L	-	-	-	-	MLH1-PMS2-	+++	+++	-	50	+	None	Local	54
2	62	24.91	IB	NSMP	2	2	H-int	+	-	+	-	+	+++	+++	+	50	+	RT	distant	34
3	75	24.61	IB	NSMP	1	3	int	+	-	-	-	+	+++	+++	+	50	+	RT	distant	3
4	68	30.86	II	p53-abn	3	6	H	+	+	+	-	+	+++	+++	+	90	+++	CT	distant	34
5	68	23.92	IIIA	NSMP	2	1	H	+	-	-	-	+	++	+++	-	30	+/+++	CT + RT	distant	43
6	45	26.45	IV	NSMP	2	5	H	+	+	+	+	+	+++	+++	+	40	+	CT + RT	distant	56
7	54	22.66	IV	p53-abn	1	1.5	H	-	+	-	-	+	+	+	-	3	+	CT + RT	distant	12

ISSN: 1472-6874